April 08, 2020 : “Bristol Myers Squibb announced that the U.S. FDA has accepted its supplemental Biologics License Application (sBLA) for Opdivo(nivolumab)plus Yervoy(ipilimumab), administered concomitantly with a limited course of chemotherapy, for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.
The FDA granted this application Priority Review with a Prescription Drug User Fee Act (PDUFA) goal date of August 6, 2020, in addition to granting Fast Track designation.”
“Additionally, the European Medicines Agency (EMA) validated a type II variation application for Opdivo plus Yervoy, combined with limited chemotherapy, for the same indication. Validation of the application confirms the submission is complete and begins the EMA’s centralized review process. This follows an announcement on March 26, 2020 that Ono Pharmaceutical Co., in partnership with Bristol Myers Squibb, submitted a supplemental application for Opdivo plus Yervoy combined with limited chemotherapy for consideration of manufacturing and marketing approval in Japan. The applications were based on results from the Phase 3 CheckMate -9LA trial. In October 2019, the company announced the trial met its primary endpoint of superior overall survival (OS) at a pre-specified interim analysis.”
“Despite treatment advances, there remains a serious unmet need for additional innovative treatment options for lung cancer patients globally,” said Sabine Maier, M.D., development lead, thoracic cancers, Bristol Myers Squibb. “The FDA’s acceptance and EMA’s validation of our applications represent important milestones for patients with lung cancer, and we look forward to working with regulatory authorities to bring the first and only dual immunotherapy plus limited chemotherapy regimen to patients as soon as possible.”
“CheckMate -9LA is an open-label, multi-center, randomized Phase 3 trial evaluating Opdivo (360 mg Q3W) plus Yervoy (1 mg/kg Q6W) combined with chemotherapy (two cycles) compared to chemotherapy alone (up to four cycles followed by optional pemetrexed maintenance therapy if eligible) as a first-line treatment in patients with metastatic non-small cell lung cancer (NSCLC) regardless of PD-L1 expression and histology. Patients in the experimental arm were treated for up to two years or until disease progression or unacceptable toxicity. Patients in the control arm were treated with up to four cycles of chemotherapy and optional pemetrexed maintenance (if eligible) until disease progression or toxicity. The primary endpoint of the trial was overall survival (OS) in the intent-to-treat population. Secondary endpoints included progression-free survival (PFS), overall response rate (ORR) and efficacy measures according to biomarkers.
Lung cancer is the leading cause of cancer deaths globally. The two main types of lung cancer are non-small cell and small cell. Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer and accounts for up to 84% of diagnoses. Survival rates vary depending on the stage and type of the cancer when diagnosed. For patients diagnosed with metastatic lung cancer, the five-year survival rate is approximately 5%.”
https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-announces-acceptance-us-and-eu-regulatory
